<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">26670245</PMID><DateCompleted><Year>2016</Year><Month>09</Month><Day>29</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1999-4915</ISSN><JournalIssue CitedMedium="Internet"><Volume>7</Volume><Issue>12</Issue><PubDate><Year>2015</Year><Month>Dec</Month><Day>08</Day></PubDate></JournalIssue><Title>Viruses</Title><ISOAbbreviation>Viruses</ISOAbbreviation></Journal><ArticleTitle>Recent Progress towards Novel EV71 Anti-Therapeutics and Vaccines.</ArticleTitle><Pagination><StartPage>6441</StartPage><EndPage>6457</EndPage><MedlinePgn>6441-57</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3390/v7122949</ELocationID><Abstract><AbstractText>Enterovirus 71 (EV71) is a group of viruses that belongs to the Picornaviridae family, which also includes viruses such as polioviruses. EV71, together with coxsackieviruses, is widely known for its association with Hand Foot Mouth Disease (HFMD), which generally affects children age five and below. Besides HFMD, EV71 can also trigger more severe and life-threatening neurological conditions such as encephalitis. Considering the lack of a vaccine and antiviral drug against EV71, together with the increasing spread of these viruses, the development of such drugs and vaccines becomes the top priority in protecting our younger generations. This article, hence, reviews some of the recent progress in the formulations of anti-therapeutics and vaccine generation for EV71, covering (i) inactivated vaccines; (ii) baculovirus-expressed vaccines against EV71; (iii) human intravenous immunoglobulin (IVIg) treatment; and (iv) the use of monoclonal antibody therapy as a prevention and treatment for EV71 infections.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ng</LastName><ForeName>Qingyong</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Animal Health Biotechnology, Temasek Life Sciences Laboratory, 1 Research Link, National University of Singapore, 117604 Singapore. qingyong@tll.org.sg.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>He</LastName><ForeName>Fang</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Animal Health Biotechnology, Temasek Life Sciences Laboratory, 1 Research Link, National University of Singapore, 117604 Singapore. hefang@tll.org.sg.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>College of Animal Sciences, Zhejiang University, Yuhangtang Road 866, Hangzhou 310013, China. hefang@tll.org.sg.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kwang</LastName><ForeName>Jimmy</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Animal Health Biotechnology, Temasek Life Sciences Laboratory, 1 Research Link, National University of Singapore, 117604 Singapore. kwanghs@163.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Microbiology Faculty of Medicine, National University of Singapore, 117604 Singapore. kwanghs@163.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>12</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Viruses</MedlineTA><NlmUniqueID>101509722</NlmUniqueID><ISSNLinking>1999-4915</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000911">Antibodies, Monoclonal</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016756">Immunoglobulins, Intravenous</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015164">Vaccines, Inactivated</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D022223">Vaccines, Subunit</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014765">Viral Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000911" MajorTopicYN="N">Antibodies, Monoclonal</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000302" MajorTopicYN="Y">isolation &amp; purification</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055808" MajorTopicYN="N">Drug Discovery</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName><QualifierName UI="Q000639" MajorTopicYN="N">trends</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D029821" MajorTopicYN="N">Enterovirus A, Human</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006232" MajorTopicYN="N">Hand, Foot and Mouth Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016756" MajorTopicYN="N">Immunoglobulins, Intravenous</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015164" MajorTopicYN="N">Vaccines, Inactivated</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000302" MajorTopicYN="N">isolation &amp; purification</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D022223" MajorTopicYN="N">Vaccines, Subunit</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000302" MajorTopicYN="N">isolation &amp; purification</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014765" MajorTopicYN="N">Viral Vaccines</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000302" MajorTopicYN="Y">isolation &amp; purification</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">anti-therapeutics</Keyword><Keyword MajorTopicYN="N">baculovirus</Keyword><Keyword MajorTopicYN="N">enterovirus 71</Keyword><Keyword MajorTopicYN="N">human intravenous immunoglobulin</Keyword><Keyword MajorTopicYN="N">inactivated vaccines</Keyword><Keyword MajorTopicYN="N">monoclonal antibodies</Keyword><Keyword MajorTopicYN="N">vaccines</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>9</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2015</Year><Month>11</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>12</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>12</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>12</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>9</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2015</Year><Month>12</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26670245</ArticleId><ArticleId IdType="pmc">PMC4690872</ArticleId><ArticleId IdType="doi">10.3390/v7122949</ArticleId><ArticleId IdType="pii">v7122949</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ranganathan S., Singh S., Poh C.L., Chow V.T. The hand, foot and mouth disease virus capsid: Sequence analysis and prediction of antigenic sites from homology modelling. Appl. Bioinform. 2002;1:43&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pubmed">15130856</ArticleId></ArticleIdList></Reference><Reference><Citation>Plevka P., Perera R., Cardosa J., Kuhn R.J., Rossmann M.G., Rossmann M.G. Crystal structure of human enterovirus 71. Science. 2012;336 doi: 10.1126/science.1218713.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1218713</ArticleId><ArticleId IdType="pmc">PMC3448362</ArticleId><ArticleId IdType="pubmed">22383808</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X., Peng W., Ren J., Hu Z., Xu J., Lou Z., Li X., Yin W., Shen X., Porta C., et al. A sensor-adaptor mechanism for enterovirus uncoating from structures of EV71. Nat. Struct. Mol. Biol. 2012;19:424&#x2013;429. doi: 10.1038/nsmb.2255.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nsmb.2255</ArticleId><ArticleId IdType="pmc">PMC3378640</ArticleId><ArticleId IdType="pubmed">22388738</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang S.-W., Cheng H.-L., Hsieh H.-Y., Chang C.-L., Tsai H.-P., Kuo P.-H., Wang S.-M., Liu C.-C., Su I.-J., Wang J.-R. Mutations in the non-structural protein region contribute to intra-genotypic evolution of Enterovirus 71. J. Biomed. Sci. 2014;21 doi: 10.1186/1423-0127-21-33.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1423-0127-21-33</ArticleId><ArticleId IdType="pmc">PMC4021180</ArticleId><ArticleId IdType="pubmed">24766641</ArticleId></ArticleIdList></Reference><Reference><Citation>Tee K.K., Lam T.T.-Y., Chan Y.F., Bible J.M., Kamarulzaman A., Tong C.Y.W., Takebe Y., Pybus O.G. Evolutionary genetics of human enterovirus 71: Origin, population dynamics, natural selection, and seasonal periodicity of the VP1 gene. J. Virol. 2010;84:3339&#x2013;3350. doi: 10.1128/JVI.01019-09.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.01019-09</ArticleId><ArticleId IdType="pmc">PMC2838098</ArticleId><ArticleId IdType="pubmed">20089660</ArticleId></ArticleIdList></Reference><Reference><Citation>Ho M., Chen E.R., Hsu K.H., Twu S.J., Chen K.T., Tsai S.F., Wang J.R., Shih S.R. An epidemic of Enterovirus 71 infection in taiwan. Taiwan enterovirus epidemic working group. N. Engl. J. Med. 1999;341:929&#x2013;935. doi: 10.1056/NEJM199909233411301.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJM199909233411301</ArticleId><ArticleId IdType="pubmed">10498487</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt N.J., Lennette E.H., Ho H.H. An apparently new enterovirus isolated from patients with disease of the central nervous system. J. Infect. Dis. 1974;129:304&#x2013;309. doi: 10.1093/infdis/129.3.304.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/129.3.304</ArticleId><ArticleId IdType="pubmed">4361245</ArticleId></ArticleIdList></Reference><Reference><Citation>Shekhar K., Lye M.S., Norlijah O., Ong F., Looi L.M., Khuzaiah R., Marzuki I., Hussein I., Wong S.L., Mohan J., et al. Deaths in children during an outbreak of hand, foot and mouth disease in peninsular malaysia&#x2014;Clinical and pathological characteristics. Med. J. Malays. 2005;60:297&#x2013;304.</Citation><ArticleIdList><ArticleId IdType="pubmed">16379183</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu C.C., Tseng H.W., Wang S.M., Wang J.R., Su I.J. An outbreak of Enterovirus 71 infection in taiwan, 1998: Epidemiologic and clinical manifestations. J. Clin. Virol. 2000;17:23&#x2013;30. doi: 10.1016/S1386-6532(00)00068-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1386-6532(00)00068-8</ArticleId><ArticleId IdType="pubmed">10814935</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang S.W., Hsu Y.W., Smith D.J., Kiang D., Tsai H.-P., Lin K.-H., Wang S.-M., Liu C.-C., Su I.-J., Wang J.R. Reemergence of Enterovirus 71 in 2008 in Taiwan: Dynamics of genetic and antigenic evolution from 1998 to 2008. J. Clin. Microbiol. 2009;47:3653&#x2013;3662. doi: 10.1128/JCM.00630-09.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JCM.00630-09</ArticleId><ArticleId IdType="pmc">PMC2772620</ArticleId><ArticleId IdType="pubmed">19776232</ArticleId></ArticleIdList></Reference><Reference><Citation>Ang L.W., Koh B.K., Chan K.P., Chua L.T., James L., Goh K.T. Epidemiology and control of hand, foot and mouth disease in Singapore, 2001&#x2013;2007. Ann. Acad. Med. Singap. 2009;38:106&#x2013;112.</Citation><ArticleIdList><ArticleId IdType="pubmed">19271036</ArticleId></ArticleIdList></Reference><Reference><Citation>Emerging Disease Surveillance and Response.  [(accessed on 1 September 2015)].  Available online:  http://www.wpro.who.int/emerging_diseases/en/</Citation></Reference><Reference><Citation>Fenner F., Henderson D.A., Arita I., Jezek Z., Ladnyi I.D. Smallpox and Its Eradication. WHO; Geneva, Switzerland: 1988.</Citation></Reference><Reference><Citation>Riedel S. Edward jenner and the history of smallpox and vaccination. Proc. Baylor Univ. Med. Cent. 2005;18:21&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1200696</ArticleId><ArticleId IdType="pubmed">16200144</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang Z.-L., Mao Q.-Y., Wang Y.-P., Zhu F.-C., Li J.-X., Yao X., Gao F., Wu X., Xu M., Wang J.-Z. Progress on the research and development of inactivated EV71 whole-virus vaccines. Hum. Vaccines Immunother. 2013;9:1701&#x2013;1705. doi: 10.4161/hv.24949.</Citation><ArticleIdList><ArticleId IdType="doi">10.4161/hv.24949</ArticleId><ArticleId IdType="pmc">PMC3906269</ArticleId><ArticleId IdType="pubmed">23744508</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang Z., Wang J. EV71 vaccine, an invaluable gift for children. Clin. Trans. Immunol. 2014;3 doi: 10.1038/cti.2014.24.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/cti.2014.24</ArticleId><ArticleId IdType="pmc">PMC4237031</ArticleId><ArticleId IdType="pubmed">25505956</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu F.-C., Meng F.-Y., Li J.-X., Li X.-L., Mao Q.-Y., Tao H., Zhang Y.-T., Yao X., Chu K., Chen Q.-H., et al. Efficacy, safety, and immunology of an inactivated alum-adjuvant Enterovirus 71 vaccine in children in China: A multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2013;381:2024&#x2013;2032. doi: 10.1016/S0140-6736(13)61049-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(13)61049-1</ArticleId><ArticleId IdType="pubmed">23726161</ArticleId></ArticleIdList></Reference><Reference><Citation>Li R., Liu L., Mo Z., Wang X., Xia J., Liang Z., Zhang Y., Li Y., Mao Q., Wang J., et al. An inactivated Enterovirus 71 vaccine in healthy children. N. Engl. J. Med. 2014;370:829&#x2013;837. doi: 10.1056/NEJMoa1303224.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1303224</ArticleId><ArticleId IdType="pubmed">24571755</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu F., Xu W., Xia J., Liang Z., Liu Y., Zhang X., Tan X., Wang L., Mao Q., Wu J., et al. Efficacy, safety, and immunogenicity of an Enterovirus 71 vaccine in China. N. Engl. J. Med. 2014;370:818&#x2013;828. doi: 10.1056/NEJMoa1304923.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1304923</ArticleId><ArticleId IdType="pubmed">24571754</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiener T.K., Premanand B., Kwang J. Immune responses to baculovirus-displayed Enterovirus 71 VP1 antigen. Expert Rev. Vaccines. 2013;12:357&#x2013;364. doi: 10.1586/erv.13.18.</Citation><ArticleIdList><ArticleId IdType="doi">10.1586/erv.13.18</ArticleId><ArticleId IdType="pubmed">23560917</ArticleId></ArticleIdList></Reference><Reference><Citation>Meng T., Kolpe A.B., Kiener T.K., Chow V.T.K., Kwang J. Display of VP1 on the surface of baculovirus and its immunogenicity against heterologous human Enterovirus 71 strains in mice. PLoS ONE. 2011;6:e21757. doi: 10.1371/journal.pone.0021757.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0021757</ArticleId><ArticleId IdType="pmc">PMC3128602</ArticleId><ArticleId IdType="pubmed">21747954</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim X.F., Jia Q., Khong W.X., Yan B., Premanand B., Alonso S., Chow V.T.K., Kwang J. Characterization of an isotype-dependent monoclonal antibody against linear neutralizing epitope effective for prophylaxis of Enterovirus 71 infection. PLoS ONE. 2012;7:e29751. doi: 10.1371/journal.pone.0029751.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0029751</ArticleId><ArticleId IdType="pmc">PMC3261156</ArticleId><ArticleId IdType="pubmed">22279543</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiener T.K., Jia Q., Meng T., Chow V.T., Kwang J. A novel universal neutralizing monoclonal antibody against Enterovirus 71 that targets the highly conserved &#x201c;knob&#x201d; region of VP3 protein. PLoS Negl. Trop. Dis. 2014;8:e2895. doi: 10.1371/journal.pntd.0002895.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pntd.0002895</ArticleId><ArticleId IdType="pmc">PMC4038473</ArticleId><ArticleId IdType="pubmed">24875055</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang G.-H., Luo Y.-J., Wu X.-Y., Si B.-Y., Lin L., Zhu Q.-Y. Monoclonal antibody induced with inactived EV71-Hn2 virus protects mice against lethal EV71-Hn2 virus infection. Virol. J. 2010;7 doi: 10.1186/1743-422X-7-106.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1743-422X-7-106</ArticleId><ArticleId IdType="pmc">PMC2887433</ArticleId><ArticleId IdType="pubmed">20500892</ArticleId></ArticleIdList></Reference><Reference><Citation>Chou A.H., Liu C.C., Chang J.Y., Jiang R., Hsieh Y.C., Tsao A., Wu C.L., Huang J.L., Fung C.P., Hsieh S.M., et al. Formalin-inactivated EV71 vaccine candidate induced cross-neutralizing antibody against subgenotypes B1, B4, B5 and C4A in adult volunteers. PLoS ONE. 2013;8:e79783. doi: 10.1371/journal.pone.0079783.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0079783</ArticleId><ArticleId IdType="pmc">PMC3836818</ArticleId><ArticleId IdType="pubmed">24278177</ArticleId></ArticleIdList></Reference><Reference><Citation>Mao Q., Cheng T., Zhu F., Li J., Wang Y., Li Y., Gao F., Yang L., Yao X., Shao J., et al. The cross-neutralizing activity of Enterovirus 71 subgenotype C4 vaccines in healthy chinese infants and children. PLoS ONE. 2013;8:e79599. doi: 10.1371/journal.pone.0079599.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0079599</ArticleId><ArticleId IdType="pmc">PMC3834186</ArticleId><ArticleId IdType="pubmed">24260259</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilton T., Dunn G., Eastwood D., Minor P.D., Martin J. Effect of formaldehyde inactivation on poliovirus. J. Virol. 2014;88:11955&#x2013;11964. doi: 10.1128/JVI.01809-14.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.01809-14</ArticleId><ArticleId IdType="pmc">PMC4178759</ArticleId><ArticleId IdType="pubmed">25100844</ArticleId></ArticleIdList></Reference><Reference><Citation>Tirado S.M., Yoon K.J. Antibody-dependent enhancement of virus infection and disease. Viral Immunol. 2003;16:69&#x2013;86. doi: 10.1089/088282403763635465.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/088282403763635465</ArticleId><ArticleId IdType="pubmed">12725690</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang S.-M., Chen I.C., Su L.-Y., Huang K.-J., Lei H.-Y., Liu C.-C. Enterovirus 71 infection of monocytes with antibody-dependent enhancement. Clin. Vaccine Immunol. CVI. 2010;17:1517&#x2013;1523. doi: 10.1128/CVI.00108-10.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/CVI.00108-10</ArticleId><ArticleId IdType="pmc">PMC2953001</ArticleId><ArticleId IdType="pubmed">20685937</ArticleId></ArticleIdList></Reference><Reference><Citation>Han J.-F., Cao R.-Y., Deng Y.-Q., Tian X., Jiang T., Qin E.D., Qin C.-F. Antibody dependent enhancement infection of Enterovirus 71 in vitro and in vivo. Virol. J. 2011;8 doi: 10.1186/1743-422X-8-106.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1743-422X-8-106</ArticleId><ArticleId IdType="pmc">PMC3060144</ArticleId><ArticleId IdType="pubmed">21385398</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao R.Y., Dong D.Y., Liu R.J., Han J.F., Wang G.C., Zhao H., Li X.F., Deng Y.Q., Zhu S.Y., Wang X.Y., et al. Human IgG subclasses against enterovirus type 71: Neutralization versus antibody dependent enhancement of infection. PLoS ONE. 2013;8:e64024. doi: 10.1371/journal.pone.0064024.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0064024</ArticleId><ArticleId IdType="pmc">PMC3659118</ArticleId><ArticleId IdType="pubmed">23700449</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen C.W., Lee Y.P., Wang Y.-F., Yu C.K. Formaldehyde-inactivated human Enterovirus 71 vaccine is compatible for co-immunization with a commercial pentavalent vaccine. Vaccine. 2011;29:2772&#x2013;2776. doi: 10.1016/j.vaccine.2011.01.094.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2011.01.094</ArticleId><ArticleId IdType="pubmed">21315698</ArticleId></ArticleIdList></Reference><Reference><Citation>Ogra P.L., Faden H., Welliver R.C. Vaccination strategies for mucosal immune responses. Clin. Microbiol. Rev. 2001;14:430&#x2013;445. doi: 10.1128/CMR.14.2.430-445.2001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/CMR.14.2.430-445.2001</ArticleId><ArticleId IdType="pmc">PMC88982</ArticleId><ArticleId IdType="pubmed">11292646</ArticleId></ArticleIdList></Reference><Reference><Citation>Jarvis D.L. Baculovirus-insect cell expression systems. Methods Enzymol. 2009;463:191&#x2013;222.</Citation><ArticleIdList><ArticleId IdType="pubmed">19892174</ArticleId></ArticleIdList></Reference><Reference><Citation>Pennock G.D., Shoemaker C., Miller L.K. Strong and regulated expression of Escherichia coli &#x3b2;-galactosidase in insect cells with a baculovirus vector. Mol. Cell. Biol. 1984;4:399&#x2013;406. doi: 10.1128/MCB.4.3.399.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/MCB.4.3.399</ArticleId><ArticleId IdType="pmc">PMC368716</ArticleId><ArticleId IdType="pubmed">6325875</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith G.E., Summers M.D., Fraser M.J. Production of human &#x3b2; interferon in insect cells infected with a baculovirus expression vector. Mol. Cell. Biol. 1983;3:2156&#x2013;2165. doi: 10.1128/MCB.3.12.2156.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/MCB.3.12.2156</ArticleId><ArticleId IdType="pmc">PMC370086</ArticleId><ArticleId IdType="pubmed">6318086</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller L.K. Baculoviruses as gene expression vectors. Annu. Rev. Microbiol. 1988;42:177&#x2013;199. doi: 10.1146/annurev.mi.42.100188.001141.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev.mi.42.100188.001141</ArticleId><ArticleId IdType="pubmed">3059993</ArticleId></ArticleIdList></Reference><Reference><Citation>Luckow V.A., Summers M.D. Trends in the development of baculovirus expression vectors. Nat. Biotechnol. 1988;6:47&#x2013;55. doi: 10.1038/nbt0188-47.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nbt0188-47</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Reilly D.R., Miller L.K., Luckow V.A. Baculovirus Expression Vectors: A Laboratory Manual. Oxford University Press on Demand; Oxford, UK: 1994.</Citation></Reference><Reference><Citation>DuBois R.M., Aguilar-Ya&#xf1;ez J.M., Mendoza-Ochoa G.I., Oropeza-Almaz&#xe1;n Y., Schultz-Cherry S., Alvarez M.M., White S.W., Russell C.J. The receptor-binding domain of influenza virus hemagglutinin produced in Escherichia coli folds into its native, immunogenic structure. J. Virol. 2011;85:865&#x2013;872. doi: 10.1128/JVI.01412-10.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.01412-10</ArticleId><ArticleId IdType="pmc">PMC3020035</ArticleId><ArticleId IdType="pubmed">21068239</ArticleId></ArticleIdList></Reference><Reference><Citation>Jifeng D., Juan P., Yingchun Z., Jinhua L. Expression of H5N1 avian influenza virus haemagglutinin in a baculovirus expression system. Chin. J. Agric. Biotechnol. 2007;4:233&#x2013;237. doi: 10.1017/S1479236207001817.</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/S1479236207001817</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruiz-Gonzalvo F., Rodriguez F., Escribano J.M. Functional and immunological properties of the baculovirus-expressed hemagglutinin of African swine fever virus. Virology. 1996;218:285&#x2013;289. doi: 10.1006/viro.1996.0193.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/viro.1996.0193</ArticleId><ArticleId IdType="pubmed">8615037</ArticleId></ArticleIdList></Reference><Reference><Citation>Rajesh Kumar S., Syed Khader S.M., Kiener T.K., Szyporta M., Kwang J. Intranasal immunization of baculovirus displayed hemagglutinin confers complete protection against mouse adapted highly pathogenic H7N7 reassortant influenza virus. PLoS ONE. 2013;8:e63856. doi: 10.1371/journal.pone.0063856.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0063856</ArticleId><ArticleId IdType="pmc">PMC3676417</ArticleId><ArticleId IdType="pubmed">23762234</ArticleId></ArticleIdList></Reference><Reference><Citation>Berger I., Fitzgerald D.J., Richmond T.J. Baculovirus expression system for heterologous multiprotein complexes. Nat. Biotechnol. 2004;22:1583&#x2013;1587. doi: 10.1038/nbt1036.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nbt1036</ArticleId><ArticleId IdType="pubmed">15568020</ArticleId></ArticleIdList></Reference><Reference><Citation>Kost T.A., Condreay J.P., Jarvis D.L. Baculovirus as versatile vectors for protein expression in insect and mammalian cells. Nat. Biotechnol. 2005;23:567&#x2013;575. doi: 10.1038/nbt1095.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nbt1095</ArticleId><ArticleId IdType="pmc">PMC3610534</ArticleId><ArticleId IdType="pubmed">15877075</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin R., Lv Z., Chen Q., Quan Y., Zhang H., Li S., Chen G., Zheng Q., Jin L., Wu X., et al. Safety and immunogenicity of H5N1 influenza vaccine based on baculovirus surface display system of Bombyx mori. PLoS ONE. 2008;3:e3933. doi: 10.1371/journal.pone.0003933.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0003933</ArticleId><ArticleId IdType="pmc">PMC2592543</ArticleId><ArticleId IdType="pubmed">19079592</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu X.G., Wang Z.S., Zhang Q., Li Z.C., Zhao H.N., Li W., Tong D.W., Liu H.J. Baculovirus surface display of e envelope glycoprotein of Japanese encephalitis virus and its immunogenicity of the displayed proteins in mouse and swine models. Vaccine. 2011;29:636&#x2013;643. doi: 10.1016/j.vaccine.2010.11.045.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2010.11.045</ArticleId><ArticleId IdType="pubmed">21115062</ArticleId></ArticleIdList></Reference><Reference><Citation>Premanand B., Kiener T.K., Meng T., Tan Y.R., Jia Q., Chow V.T., Kwang J. Induction of protective immune responses against EV71 in mice by baculovirus encoding a novel expression cassette for capsid protein VP1. Antivir. Res. 2012;95:311&#x2013;315. doi: 10.1016/j.antiviral.2012.05.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2012.05.017</ArticleId><ArticleId IdType="pubmed">22691220</ArticleId></ArticleIdList></Reference><Reference><Citation>Rold&#xe3;o A., Mellado M.C.M., Castilho L.R., Carrondo M.J.T., Alves P.M. Virus-like particles in vaccine development. Expert Rev. Vaccines. 2010;9:1149&#x2013;1176. doi: 10.1586/erv.10.115.</Citation><ArticleIdList><ArticleId IdType="doi">10.1586/erv.10.115</ArticleId><ArticleId IdType="pubmed">20923267</ArticleId></ArticleIdList></Reference><Reference><Citation>Mariani L., Venuti A. Hpv vaccine: An overview of immune response, clinical protection, and new approaches for the future. J. Transl. Med. 2010;8 doi: 10.1186/1479-5876-8-105.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1479-5876-8-105</ArticleId><ArticleId IdType="pmc">PMC2988719</ArticleId><ArticleId IdType="pubmed">20979636</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung C.-Y., Chen C.-Y., Lin S.-Y., Chung Y.-C., Chiu H.-Y., Chi W.-K., Lin Y.-L., Chiang B.-L., Chen W.-J., Hu Y.-C. Enterovirus 71 virus-like particle vaccine: Improved production conditions for enhanced yield. Vaccine. 2010;28:6951&#x2013;6957. doi: 10.1016/j.vaccine.2010.08.052.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2010.08.052</ArticleId><ArticleId IdType="pubmed">20797455</ArticleId></ArticleIdList></Reference><Reference><Citation>Ku Z., Ye X., Huang X., Cai Y., Liu Q., Li Y., Su Z., Huang Z. Neutralizing antibodies induced by recombinant virus-like particles of Enterovirus 71 genotype C4 inhibit infection at pre- and post-attachment steps. PLoS ONE. 2013;8:e57601. doi: 10.1371/journal.pone.0057601.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0057601</ArticleId><ArticleId IdType="pmc">PMC3579802</ArticleId><ArticleId IdType="pubmed">23451250</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin S.Y., Yeh C.T., Li W.H., Yu C.P., Lin W.C., Yang J.Y., Wu H.L., Hu Y.C. Enhanced Enterovirus 71 virus-like particle yield from a new baculovirus design. Biotechnol. Bioeng. 2015;112:2005&#x2013;2015. doi: 10.1002/bit.25625.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/bit.25625</ArticleId><ArticleId IdType="pmc">PMC7161748</ArticleId><ArticleId IdType="pubmed">25997678</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao L., Yi Y., Song J.-D., Tian M.-M., Tian R.-G., Meng Q.-L., Qiu F., Jia Z.-Y., Bi S.L. The assemblage, purification and characterization of EV71 VLPs expressed in baculovirus. Chin. J. Virol. 2012;28:201&#x2013;206. (In Chinese)</Citation><ArticleIdList><ArticleId IdType="pubmed">22764520</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitford M., Stewart S., Kuzio J., Faulkner P. Identification and sequence analysis of a gene encoding GP67, an abundant envelope glycoprotein of the baculovirus autographa californica nuclear polyhedrosis virus. J. Virol. 1989;63:1393&#x2013;1399.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC247838</ArticleId><ArticleId IdType="pubmed">2644449</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu C.-C., Chou A.-H., Lien S.-P., Lin H.-Y., Liu S.-J., Chang J.-Y., Guo M.-S., Chow Y.-H., Yang W.-S., Chang K.H.-W. Identification and characterization of a cross-neutralization epitope of Enterovirus 71. Vaccine. 2011;29:4362&#x2013;4372. doi: 10.1016/j.vaccine.2011.04.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2011.04.010</ArticleId><ArticleId IdType="pubmed">21501643</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee H., Cifuente J.O., Ashley R.E., Conway J.F., Makhov A.M., Tano Y., Shimizu H., Nishimura Y., Hafenstein S. A strain-specific epitope of Enterovirus 71 identified by cryo-electron microscopy of the complex with fab from neutralizing antibody. J. Virol. 2013;87:11363&#x2013;11370. doi: 10.1128/JVI.01926-13.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.01926-13</ArticleId><ArticleId IdType="pmc">PMC3807339</ArticleId><ArticleId IdType="pubmed">23946455</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu L., He D., Li Z., Zheng J., Yang L., Yu M., Yu H., Chen Y., Que Y., Shih J.W.K., et al. Protection against lethal enterovirus 71 challenge in mice by a recombinant vaccine candidate containing a broadly cross-neutralizing epitope within the VP2 EF loop. Theranostics. 2014;4:498&#x2013;513. doi: 10.7150/thno.7457.</Citation><ArticleIdList><ArticleId IdType="doi">10.7150/thno.7457</ArticleId><ArticleId IdType="pmc">PMC3964443</ArticleId><ArticleId IdType="pubmed">24669278</ArticleId></ArticleIdList></Reference><Reference><Citation>He D.L., Xia N.S., Xu F.H., Cheng T., Weng Z.X., Ge S.X., Chen Y.X., Chen Z.M. Enterovirus 71 Neutralized Epitope Polypeptide and Application Thereof. CN102690327 A. 2012 Sep 26;</Citation></Reference><Reference><Citation>Deng Y.-Q., Ma J., Xu L.-J., Li Y.-X., Zhao H., Han J.-F., Tao J., Li X.-F., Zhu S.-Y., Qin E.D., et al. Generation and characterization of a protective mouse monoclonal antibody against human enterovirus 71. Appl. Microbiol. Biotechnol. 2015;99:7663&#x2013;7671.</Citation><ArticleIdList><ArticleId IdType="pubmed">25967656</ArticleId></ArticleIdList></Reference><Reference><Citation>Shingler K.L., Cifuente J.O., Ashley R.E., Makhov A.M., Conway J.F., Hafenstein S. The enterovirus 71 procapsid binds neutralizing antibodies and rescues virus infection in vitro. J. Virol. 2015;89:1900&#x2013;1908. doi: 10.1128/JVI.03098-14.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.03098-14</ArticleId><ArticleId IdType="pmc">PMC4300772</ArticleId><ArticleId IdType="pubmed">25428877</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin T., Xianyu L., Lyu S. Monoclonal neutralizing antibodies against ev71 screened from mice immunized with yeast-produced virus-like particles. Virol. Sin. 2015;30:208&#x2013;213. doi: 10.1007/s12250-015-3573-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12250-015-3573-8</ArticleId><ArticleId IdType="pmc">PMC8200868</ArticleId><ArticleId IdType="pubmed">26040893</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu L., Huang K.J., Ho T.S., Liu C.C., Lee Y.R., Lin C.Y., Shiuan D., Jiang X.H. Monoclonal antibodies for diagnosis of Enterovirus 71. Monoclon. Antib. Immunodiagn. Immunother. 2013;32:386&#x2013;394. doi: 10.1089/mab.2013.0033.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/mab.2013.0033</ArticleId><ArticleId IdType="pubmed">24328741</ArticleId></ArticleIdList></Reference><Reference><Citation>Prabakaran M., Velumani S., He F., Karuppannan A.K., Geng G.Y., Yin L.K., Kwang J. Protective immunity against influenza h5n1 virus challenge in mice by intranasal co-administration of baculovirus surface-displayed HA and recombinant CTB as an adjuvant. Virology. 2008;380:412&#x2013;420. doi: 10.1016/j.virol.2008.08.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virol.2008.08.002</ArticleId><ArticleId IdType="pubmed">18786689</ArticleId></ArticleIdList></Reference><Reference><Citation>Suzuki T., Chang M.O., Kitajima M., Takaku H. Baculovirus activates murine dendritic cells and induces non-specific NK cell and T cell immune responses. Cell. Immunol. 2010;262:35&#x2013;43. doi: 10.1016/j.cellimm.2009.12.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cellimm.2009.12.005</ArticleId><ArticleId IdType="pubmed">20060108</ArticleId></ArticleIdList></Reference><Reference><Citation>Prabakaran M., Meng T., He F., Yunrui T., Qiang J., Lin R.T., Kwang J. Subcutaneous immunization with baculovirus surface-displayed hemagglutinin of pandemic H1N1 influenza A virus induces protective immunity in mice. Clin. Vaccine Immunol. 2011;18:1582&#x2013;1585. doi: 10.1128/CVI.05114-11.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/CVI.05114-11</ArticleId><ArticleId IdType="pmc">PMC3165240</ArticleId><ArticleId IdType="pubmed">21752948</ArticleId></ArticleIdList></Reference><Reference><Citation>Gronowski A.M., Hilbert D.M., Sheehan K.C., Garotta G., Schreiber R.D. Baculovirus stimulates antiviral effects in mammalian cells. J. Virol. 1999;73:9944&#x2013;9951.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC113044</ArticleId><ArticleId IdType="pubmed">10559307</ArticleId></ArticleIdList></Reference><Reference><Citation>Syed Musthaq S., Madhan S., Sahul Hameed A.S., Kwang J. Localization of VP28 on the baculovirus envelope and its immunogenicity against white spot syndrome virus in penaeus monodon. Virology. 2009;391:315&#x2013;324. doi: 10.1016/j.virol.2009.06.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virol.2009.06.017</ArticleId><ArticleId IdType="pubmed">19604531</ArticleId></ArticleIdList></Reference><Reference><Citation>Murges D., Kremer A. Knebel-Morsdorf, D. Baculovirus transactivator ie1 is functional in mammalian cells. J. Gen. Virol. 1997;78:1507&#x2013;1510. doi: 10.1099/0022-1317-78-6-1507.</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/0022-1317-78-6-1507</ArticleId><ArticleId IdType="pubmed">9191949</ArticleId></ArticleIdList></Reference><Reference><Citation>Leung C.S.K. Endogenous antigen presentation of MHC class II epitopes through non-autophagic pathways. Front. Immunol. 2015;6 doi: 10.3389/fimmu.2015.00464.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2015.00464</ArticleId><ArticleId IdType="pmc">PMC4563256</ArticleId><ArticleId IdType="pubmed">26441969</ArticleId></ArticleIdList></Reference><Reference><Citation>Diebold S.S., Cotten M., Koch N., Zenke M. Mhc class II presentation of endogenously expressed antigens by transfected dendritic cells. Gene Ther. 2001;8:487&#x2013;493. doi: 10.1038/sj.gt.3301433.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.gt.3301433</ArticleId><ArticleId IdType="pubmed">11313828</ArticleId></ArticleIdList></Reference><Reference><Citation>McHeyzer-Williams M., Okitsu S., Wang N., McHeyzer-Williams L. Molecular programming of B cell memory. Nat. Rev. Immunol. 2012;12:24&#x2013;34. doi: 10.1038/nri3128.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri3128</ArticleId><ArticleId IdType="pmc">PMC3947622</ArticleId><ArticleId IdType="pubmed">22158414</ArticleId></ArticleIdList></Reference><Reference><Citation>Murphy K.P., Travers P., Walport M., Janeway C. Janeway&#x2019;s Immunobiology. Garland Science; New York, NY, USA: 2008.</Citation></Reference><Reference><Citation>Cruz I., Meijer C.J.L.M., Walboomers J.M.M., Snijders P.J.F., Waal I.V.D. Lack of MHC class I surface expression on neoplastic cells and poor activation of the secretory pathway of cytotoxic cells in oral squamous cell carcinomas. Br. J. Cancer. 1999;81:881&#x2013;889. doi: 10.1038/sj.bjc.6690780.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.bjc.6690780</ArticleId><ArticleId IdType="pmc">PMC2374311</ArticleId><ArticleId IdType="pubmed">10555762</ArticleId></ArticleIdList></Reference><Reference><Citation>Ura T., Okuda K., Shimada M. Developments in viral vector-based vaccines. Vaccines. 2014;2:624&#x2013;641. doi: 10.3390/vaccines2030624.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines2030624</ArticleId><ArticleId IdType="pmc">PMC4494222</ArticleId><ArticleId IdType="pubmed">26344749</ArticleId></ArticleIdList></Reference><Reference><Citation>Jolles S., Sewell W.A.C., Misbah S.A. Clinical uses of intravenous immunoglobulin. Clin. Exp. Immunol. 2005;142:1&#x2013;11. doi: 10.1111/j.1365-2249.2005.02834.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2249.2005.02834.x</ArticleId><ArticleId IdType="pmc">PMC1809480</ArticleId><ArticleId IdType="pubmed">16178850</ArticleId></ArticleIdList></Reference><Reference><Citation>Hughes R.A., Wijdicks E.F., Barohn R., Benson E., Cornblath D.R., Hahn A.F., Meythaler J.M., Miller R.G., Sladky J.T., Stevens J.C. Practice parameter: Immunotherapy for guillain-barre syndrome: Report of the quality standards subcommittee of the american academy of neurology. Neurology. 2003;61:736&#x2013;740. doi: 10.1212/WNL.61.6.736.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.61.6.736</ArticleId><ArticleId IdType="pubmed">14504313</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang S.M., Lei H.Y., Huang M.-C., Su L.-Y., Lin H.-C., Yu C.-K., Wang J.-L., Liu C.C. Modulation of cytokine production by intravenous immunoglobulin in patients with Enterovirus 71-associated brainstem encephalitis. J. Clin. Virol. 2006;37:47&#x2013;52. doi: 10.1016/j.jcv.2006.05.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcv.2006.05.009</ArticleId><ArticleId IdType="pubmed">16861032</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang S.M., Ho T.S., Shen C.-F., Liu C.C. Enterovirus 71, one virus and many stories. Pediatr. Neonatol. 2008;49:113&#x2013;115. doi: 10.1016/S1875-9572(08)60024-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1875-9572(08)60024-8</ArticleId><ArticleId IdType="pubmed">19054915</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao R., Han J., Deng Y., Yu M., Qin E., Qin C. Presence of high-titer neutralizing antibodies against Enterovirus 71 in intravenous immunoglobulin manufactured from Chinese donors. Clin. Infect. Dis. 2010;50:125&#x2013;126. doi: 10.1086/649012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/649012</ArticleId><ArticleId IdType="pubmed">20001529</ArticleId></ArticleIdList></Reference><Reference><Citation>Bayry J., Lacroix-Desmazes S., Kazatchkine M.D., Kaveri S.V. Intravenous immunoglobulin for infectious diseases: Back to the pre-antibiotic and passive prophylaxis era? Trends Pharmacol. Sci. 2004;25:306&#x2013;310. doi: 10.1016/j.tips.2004.04.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tips.2004.04.002</ArticleId><ArticleId IdType="pmc">PMC7127229</ArticleId><ArticleId IdType="pubmed">15165745</ArticleId></ArticleIdList></Reference><Reference><Citation>Teeling J.L., Jansen-Hendriks T., Kuijpers T.W., de Haas M., van de Winkel J.G., Hack C.E., Bleeker W.K. Therapeutic efficacy of intravenous immunoglobulin preparations depends on the immunoglobulin G dimers: Studies in experimental immune thrombocytopenia. Blood. 2001;98:1095&#x2013;1099. doi: 10.1182/blood.V98.4.1095.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood.V98.4.1095</ArticleId><ArticleId IdType="pubmed">11493456</ArticleId></ArticleIdList></Reference><Reference><Citation>Nimmerjahn F., Ravetch J.V. The antiinflammatory activity of IgG: The intravenous IgG paradox. J. Exp. Med. 2007;204:11&#x2013;15. doi: 10.1084/jem.20061788.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20061788</ArticleId><ArticleId IdType="pmc">PMC2118416</ArticleId><ArticleId IdType="pubmed">17227911</ArticleId></ArticleIdList></Reference><Reference><Citation>Ameratunga R., Sinclair J., Kolbe J. Increased risk of adverse events when changing intravenous immunoglobulin preparations. Clin. Exp. Immunol. 2004;136:111&#x2013;113. doi: 10.1111/j.1365-2249.2004.02412.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2249.2004.02412.x</ArticleId><ArticleId IdType="pmc">PMC1809000</ArticleId><ArticleId IdType="pubmed">15030521</ArticleId></ArticleIdList></Reference><Reference><Citation>Feldmeyer L., Benden C., Haile S.R., Boehler A., Speich R., French L.E., Hofbauer G.F. Not all intravenous immunoglobulin preparations are equally well tolerated. Acta Derm. Venereol. 2010;90:494&#x2013;497. doi: 10.2340/00015555-0900.</Citation><ArticleIdList><ArticleId IdType="doi">10.2340/00015555-0900</ArticleId><ArticleId IdType="pubmed">20814625</ArticleId></ArticleIdList></Reference><Reference><Citation>Schiff R.I. Transmission of viral infections through intravenous immune globulin. N. Engl. J. Med. 1994;331:1649&#x2013;1650. doi: 10.1056/NEJM199412153312409.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJM199412153312409</ArticleId><ArticleId IdType="pubmed">7969346</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang W., Wang E.Q., Balthasar J.P. Monoclonal antibody pharmacokinetics and pharmacodynamics. Clin. Pharmacol. Ther. 2008;84:548&#x2013;558. doi: 10.1038/clpt.2008.170.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/clpt.2008.170</ArticleId><ArticleId IdType="pubmed">18784655</ArticleId></ArticleIdList></Reference><Reference><Citation>Yokoyama W.M., Christensen M., Dos Santos G., Miller D., Ho J., Wu T., Dziegelewski M., Neethling F.A. Production of monoclonal antibodies. Curr. Prot. Immunol. 2006 doi: 10.1002/0471142735.im0205s102.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/0471142735.im0205s102</ArticleId><ArticleId IdType="pubmed">24510488</ArticleId></ArticleIdList></Reference><Reference><Citation>Sgro C. Side-effects of a monoclonal antibody, muromonab CD3/orthoclone OKT3: Bibliographic review. Toxicology. 1995;105:23&#x2013;29. doi: 10.1016/0300-483X(95)03123-W.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0300-483X(95)03123-W</ArticleId><ArticleId IdType="pubmed">8638282</ArticleId></ArticleIdList></Reference><Reference><Citation>Lubeck M.D., Steplewski Z., Baglia F., Klein M.H., Dorrington K.J., Koprowski H. The interaction of murine IgG subclass proteins with human monocyte fc receptors. J. Immunol. 1985;135:1299&#x2013;1304.</Citation><ArticleIdList><ArticleId IdType="pubmed">3159790</ArticleId></ArticleIdList></Reference><Reference><Citation>McCool D., Birshtein B.K., Painter R.H. Structural requirements of immunoglobulin G for binding to the Fc &#x3b3; receptors of the human tumor cell lines U937, HL-60, ML-1, AND K562. J. Immunol. 1985;135:1975&#x2013;1980.</Citation><ArticleIdList><ArticleId IdType="pubmed">3860563</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang H., Ma C., Lu Y., Ji X., Pang Y., Hua F., Cui L., Ba D., He W. Generation of human neutralizing monoclonal antibodies against the 2009 pandemic H1N1 virus from peripheral blood memory b lymphocytes. Cell. Mol. Immunol. 2013;10:403&#x2013;412. doi: 10.1038/cmi.2013.25.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/cmi.2013.25</ArticleId><ArticleId IdType="pmc">PMC4003197</ArticleId><ArticleId IdType="pubmed">23912783</ArticleId></ArticleIdList></Reference><Reference><Citation>Traggiai E., Becker S., Subbarao K., Kolesnikova L., Uematsu Y., Gismondo M.R., Murphy B.R., Rappuoli R., Lanzavecchia A. An efficient method to make human monoclonal antibodies from memory B cells: Potent neutralization of SARS coronavirus. Nat. Med. 2004;10:871&#x2013;875. doi: 10.1038/nm1080.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm1080</ArticleId><ArticleId IdType="pmc">PMC7095806</ArticleId><ArticleId IdType="pubmed">15247913</ArticleId></ArticleIdList></Reference><Reference><Citation>Harding F.A., Stickler M.M., Razo J., DuBridge R.B. The immunogenicity of humanized and fully human antibodies: Residual immunogenicity resides in the CDR regions. mAbs. 2010;2:256&#x2013;265. doi: 10.4161/mabs.2.3.11641.</Citation><ArticleIdList><ArticleId IdType="doi">10.4161/mabs.2.3.11641</ArticleId><ArticleId IdType="pmc">PMC2881252</ArticleId><ArticleId IdType="pubmed">20400861</ArticleId></ArticleIdList></Reference><Reference><Citation>Jakobovits A. Production of fully human antibodies by transgenic mice. Curr. Opin. Biotechnol. 1995;6:561&#x2013;566. doi: 10.1016/0958-1669(95)80093-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0958-1669(95)80093-X</ArticleId><ArticleId IdType="pubmed">7579668</ArticleId></ArticleIdList></Reference><Reference><Citation>Lonberg N. Human antibodies from transgenic animals. Nat. Biotechnol. 2005;23:1117&#x2013;1125. doi: 10.1038/nbt1135.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nbt1135</ArticleId><ArticleId IdType="pubmed">16151405</ArticleId></ArticleIdList></Reference><Reference><Citation>Lonberg N., Taylor L.D., Harding F.A., Trounstine M., Higgins K.M., Schramm S.R., Kuo C.C., Mashayekh R., Wymore K., McCabe J.G., et al. Antigen-specific human antibodies from mice comprising four distinct genetic modifications. Nature. 1994;368:856&#x2013;859. doi: 10.1038/368856a0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/368856a0</ArticleId><ArticleId IdType="pubmed">8159246</ArticleId></ArticleIdList></Reference><Reference><Citation>Green L.L., Hardy M.C., Maynard-Currie C.E., Tsuda H., Louie D.M., Mendez M.J., Abderrahim H., Noguchi M., Smith D.H., Zeng Y., David N.E., et al. Antigen-specific human monoclonal antibodies from mice engineered with human Ig heavy and light chain YACs. Nat. Genet. 1994;7:13&#x2013;21. doi: 10.1038/ng0594-13.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng0594-13</ArticleId><ArticleId IdType="pubmed">8075633</ArticleId></ArticleIdList></Reference><Reference><Citation>Carter P.J. Potent antibody therapeutics by design. Nat. Rev. Immunol. 2006;6:343&#x2013;357.</Citation><ArticleIdList><ArticleId IdType="pubmed">16622479</ArticleId></ArticleIdList></Reference><Reference><Citation>Br&#xfc;ggemann M., Caskey H.M., Teale C., Waldmann H., Williams G.T., Surani M.A., Neuberger M.S. A repertoire of monoclonal antibodies with human heavy chains from transgenic mice. Proc. Natl. Acad. Sci. USA. 1989;86:6709&#x2013;6713. doi: 10.1073/pnas.86.17.6709.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.86.17.6709</ArticleId><ArticleId IdType="pmc">PMC297915</ArticleId><ArticleId IdType="pubmed">2505258</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuberger M.S., Williams G.T., Mitchell E.B., Jouhal S.S., Flanagan J.G., Rabbitts T.H. A hapten-specific chimaeric IgE antibody with human physiological effector function. Nature. 1985;314:268&#x2013;270. doi: 10.1038/314268a0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/314268a0</ArticleId><ArticleId IdType="pubmed">2580239</ArticleId></ArticleIdList></Reference><Reference><Citation>Morrison S.L., Johnson M.J., Herzenberg L.A., Oi V.T. Chimeric human antibody molecules: Mouse antigen-binding domains with human constant region domains. Proc. Natl. Acad. Sci. USA. 1984;81:6851&#x2013;6855. doi: 10.1073/pnas.81.21.6851.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.81.21.6851</ArticleId><ArticleId IdType="pmc">PMC392030</ArticleId><ArticleId IdType="pubmed">6436822</ArticleId></ArticleIdList></Reference><Reference><Citation>Gorman S.D., Clark M.R. Humanisation of monoclonal antibodies for therapy. Semin. Immunol. 1990;2:457&#x2013;466.</Citation><ArticleIdList><ArticleId IdType="pubmed">2104282</ArticleId></ArticleIdList></Reference><Reference><Citation>Hwang W.Y., Foote J. Immunogenicity of engineered antibodies. Methods. 2005;36:3&#x2013;10. doi: 10.1016/j.ymeth.2005.01.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ymeth.2005.01.001</ArticleId><ArticleId IdType="pubmed">15848070</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan Y., Ng Q., Jia Q., Kwang J., He F. A novel humanized antibody neutralizes H5N1 influenza virus via two different mechanisms. J. Virol. 2015;89:3712&#x2013;3722. doi: 10.1128/JVI.03014-14.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.03014-14</ArticleId><ArticleId IdType="pmc">PMC4403434</ArticleId><ArticleId IdType="pubmed">25609802</ArticleId></ArticleIdList></Reference><Reference><Citation>Janeway C.A., Travers P., Walport M., Shlomchik M.J. Garland Science; New York, NY, USA: 2001. Structural variation in immunoglobulin constant regions.</Citation></Reference><Reference><Citation>Stewart R., Hammond S.A., Oberst M., Wilkinson R.W. The role of Fc &#x3b3; receptors in the activity of immunomodulatory antibodies for cancer. J. ImmunoTher. Cancer. 2014;2:29. doi: 10.1186/s40425-014-0029-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40425-014-0029-x</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>